Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

Richard Haubrich,Daniel Berger,Philippe Chiliade,Amy E. Colson,Marcus A. Conant,Joel E. Gallant,Timothy Wilkin,Jeffrey P. Nadler,Gerald Pierone,Michael S. Saag,Ben van Baelen,Eric Lefebvre

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

2007

Richard Haubrich
Daniel Berger
Philippe Chiliade
Amy E. Colson
Marcus A. Conant
Joel E. Gallant
Timothy Wilkin
Jeffrey P. Nadler
Gerald Pierone
Michael S. Saag
Ben van Baelen
Eric Lefebvre

Background:Agents for the treatment of HIV-1-infected patients with resistance to current antiretroviral (ART) drugs are needed.Methods:TMC114-C202 was a randomized, partially blinded, dose-finding study in treatment-experienced HIV-1-infected patients with one or more primary protease inhibitor (PI

Keywords:

Medicine
Protease
Ritonavir
Virology
Immunology
Lopinavir
Darunavir
Viral disease
Sida
Immunopathology
Enzyme inhibitor
Regimen
Discontinuation
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations